Boston Scientific (BSX): analysis in plain words
Is Boston Scientific cheap or expensive? How it makes money, whether it grows and its risks, explained in plain words and with its official accounts.
Boston Scientific (BSX) is listed on the NYSE and we classify it in healthcare and pharma. Below are its key dated figures, how it makes money, how it compares with its sector, what works for and against Boston Scientific according to those figures, and the questions people ask most about the stock. No buy or sell tips.
Boston Scientific (BSX) key figures as of November 4, 2026
| Figure | Value | What it measures |
|---|---|---|
| Share price | $45.82 | Last price on November 4, 2026 |
| P/E ratio (TTM) | 19.3x | Price over earnings per share |
| Revenue growth | +1.4% | Latest quarter vs the same quarter a year earlier |
| Net margin (TTM) | 16.6% | Profit for every 100 of sales |
| Net debt / EBITDA | 2.0x | Years of operating profit to repay debt |
| Dividend yield | 0.00% | Annual dividend over price |
| Market cap | $66.4 billion | What the stock market values it at |
The Boston Scientific figures come from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026. Any BSX figure that is not available shows as N/A: we do not estimate it.
How Boston Scientific makes money
Boston Scientific makes devices for minimally invasive procedures. Its Cardiovascular segment, the larger one, includes the Farapulse ablation system, the Watchman heart implant and stents, while MedSurg covers endoscopy, urology and neuromodulation products. Customers are hospitals and clinics across the United States, Europe and Asia.
Over the last 12 months, Boston Scientific brought in revenue of $21.1 billion. For every 100 it sells, Boston Scientific keeps 68.0 after the direct cost of what it sells (gross margin) and 19.1 after all operating costs (operating margin). With 59,000 full-time employees, that is about $357,000 of revenue per employee.
Boston Scientific against its sector
To know whether a Boston Scientific figure is high or low you have to put it next to similar companies. This table compares Boston Scientific with the median of the 30 healthcare and pharma companies Fintols covers, with data as of November 4, 2026.
| Figure | Boston Scientific | healthcare and pharma median |
|---|---|---|
| P/E | 19.3x | 31.3x (30) |
| Revenue growth | +1.4% | +8.3% (33) |
| Net margin | 16.6% | 14.9% (33) |
| Dividend yield | 0.00% | 1.52% (33) |
| Net debt / EBITDA | 2.0x | 1.6x (31) |
In short, against the typical healthcare and pharma company, Boston Scientific trades on a lower P/E, grows more slowly and pays a lower dividend yield. By size, Boston Scientific ranks number 24 of 28 healthcare and pharma companies quoted in USD on Fintols.
The bull case for Boston Scientific
These are the strengths in the Boston Scientific figures as of November 4, 2026:
- On a P/E basis Boston Scientific trades cheaper than its sector: 19.3x its annual earnings, against 31.3x for the healthcare and pharma median (30 companies with data).
- Analysts expect Boston Scientific earnings to rise: its P/E on the next 12 months of estimated earnings is 14.6x, below the current 19.3x.
The main risk for Boston Scientific
Boston Scientific stock sits 57% below its 52-week high ($105.65): the market has cut its expectations, and it is worth understanding why first.
And, like the rest of healthcare and pharma, Boston Scientific is exposed to a key drug losing patent protection or a clinical trial failing, plus government pressure on prices.
Frequently asked questions about Boston Scientific
Is it a good time to buy Boston Scientific stock?
Fintols does not tell you whether to buy or sell Boston Scientific, and nobody knows what the price will do tomorrow. What we can show you is where it stands today. As of November 4, 2026, Boston Scientific stock trades at $45.82, 57% below its 52-week high ($105.65) and 16% above its low ($39.57). Its P/E is 19.3x against a healthcare and pharma median of 31.3x, and 14.6x on the earnings analysts expect over the next 12 months. With Boston Scientific, as with any stock, timing matters less than understanding the business, investing for the long run and not betting everything on a single company.
Does Boston Scientific pay a dividend?
No. As of November 4, 2026, Boston Scientific does not pay a dividend: what it earns stays in the company to grow, invest or, where it does so, buy back shares. Anyone buying Boston Scientific today is counting on the share price rising, not on income.
Is Boston Scientific stock expensive?
It depends on what you compare it with. On P/E, Boston Scientific trades at 19.3x its last 12 months of earnings: cheaper than the healthcare and pharma median (31.3x). Including its debt, Boston Scientific is valued at 13.4x its EBITDA (EV/EBITDA). A high P/E alone does not make Boston Scientific expensive: it can be justified if earnings grow fast, and a low one can reflect a business in trouble.
Who are Boston Scientific's competitors?
On Fintols we compare Boston Scientific with Vertex, Stryker and Novo Nordisk, which are also in healthcare and pharma. As of November 4, 2026, Vertex is worth $139.2 billion and trades on a P/E of 36.8; Stryker is worth $129.3 billion and trades on a P/E of 36.2; Novo Nordisk is worth $186.0 billion and trades on a P/E of 10.3. Each has a side-by-side comparison with Boston Scientific below.
Boston Scientific competitors
- Vertex (VRTX) analysis · Boston Scientific vs Vertex comparison
- Stryker (SYK) analysis · Boston Scientific vs Stryker comparison
- Novo Nordisk (NVO) analysis · Boston Scientific vs Novo Nordisk comparison
To understand Boston Scientific better
- DCF and WACC Explained: A Practical Valuation Guide
- P/E Ratio and EPS Explained: How to Read Them Without Traps
More companies like Boston Scientific: healthcare and pharma stocks and S&P 500 companies. Open the full BSX analysis with its valuation and scenarios. Educational content about Boston Scientific, not investment advice.